PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 22, 2021SHILAP Revista de lepidopterología35 citationsOpen Access

Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience

MDMarie D’hoogheBWBarbara WillekensVDValérie Delvaux

Key Points

Key points are not available for this paper at this time.

Abstract

More than 60% of the patients with MS who started add-on treatment with cannabinoid oromucosal spray reported a clinically relevant symptomatic effect and continued treatment after 12 weeks.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

D’hooghe et al. (2021) studied this question.

synapsesocial.com/papers/69d71fdf424c1fc5df563803https://doi.org/10.1186/s12883-021-02246-0
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice2016 · 52 citations
  2. 2Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity2016 · 116 citations
  3. 3Natural History of Multiple Sclerosis Symptoms2013 · 465 citations
  4. 4An international survey of patients living with spasticity2016 · 62 citations
  5. 5Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis2007 · 382 citations